⌘K
hVIVO has been selected to run the world’s first pivotal Phase III human challenge trial in whooping cough, marking a major scientific milestone and its largest study to date. The contract strengthens revenue visibility into 2026–27 while underlining the growing importance of human challenge trials in accelerating vaccine approvals globally.
